Herbs (Global Traditional) · Southeast Asian
Pueraria mirifica
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Pueraria mirifica is a Thai herb containing phytoestrogens like miroestrol and deoxymiroestrol that bind to estrogen receptors. Clinical studies show it reduces vaginal dryness and improves vaginal health markers in postmenopausal women.
Pueraria mirifica is a tropical herb native to Thailand and neighboring Southeast Asian regions, belonging to the legume family (Fabaceae). It is sourced from the tuberous roots of the plant (also known as Pueraria candollei var. mirifica) and typically extracted using solvent extraction methods to produce standardized capsules or powders. The herb contains potent estrogenic phytoestrogens, particularly miroestrol and deoxymiroestrol.
Clinical evidence includes RCTs with 71 postmenopausal women showing improved vaginal health and bone markers at 20-50 mg/day for 24 weeks (PMIDs: 17415017, 18202589). A systematic review of 8 studies (309 patients) found ~50% reduction in climacteric scores, though conclusions were limited by methodological flaws and lack of standardization (PMID: 29409850). No large meta-analyses have been conducted.
Clinically studied doses: 20-50 mg/day of capsule extract for 24 weeks for menopausal and vaginal symptoms. Studies used standardized extracts though specific standardization details (% miroestrol) were not consistently reported. No maximum safe dose has been established. Consult a healthcare provider before starting any new supplement.
Pueraria mirifica is not consumed as a food ingredient for macronutrient content but rather as a phytoestrogenic botanical supplement. Macronutrient composition of the dried root/tuberous root: carbohydrates predominate (~70-75% dry weight, primarily starch and soluble sugars), protein (~5-8% dry weight), fat (~1-2% dry weight), crude fiber (~8-12% dry weight). The primary bioactive compounds are phytoestrogens, with total isoflavone content ranging from approximately 0.5-10% dry weight depending on geographic origin, harvest season, and plant age. Key identified phytoestrogens include: miroestrol (unique to P. mirifica, ~0.002-0.01% dry weight, considered the most potent phytoestrogen known with estrogenic activity approximately 3,000x that of daidzein relative to estradiol binding affinity), deoxymiroestrol (~0.001-0.005% dry weight, oxidizes to miroestrol), isomiroestrol, puerarin (major isoflavone, ~1-3% dry weight), daidzein (~0.1-0.5% dry weight), daidzin (~0.2-0.8% dry weight), genistein (~0.05-0.2% dry weight), genistin, formononetin, biochanin A, kwakhurin, mirificin, and coumestrol (~trace to 0.05% dry weight). Also contains chromenes: tuberosin and related compounds. Bioavailability notes: miroestrol and deoxymiroestrol are relatively lipophilic and absorbed via passive diffusion; puerarin has moderate oral bioavailability (~20-35%) limited by poor aqueous solubility but enhanced by gut microbiome hydrolysis of glycosides to aglycones; coumestrol has higher estrogenic receptor binding affinity than most isoflavones (ERβ selective). Mineral content is modest: potassium (~800-1,200 mg/100g dry weight), calcium (~150-300 mg/100g dry weight), phosphorus (~100-200 mg/100g dry weight), magnesium (~50-100 mg/100g dry weight), iron (~2-5 mg/100g dry weight). Vitamin content is limited: small amounts of B vitamins (thiamine, riboflavin at <0.5 mg/100g dry weight each) and trace vitamin C. Standardized commercial extracts are typically normalized to total isoflavone content (20-40% standardized extracts) or specifically to miroestrol/deoxymiroestrol content. Note: significant inter-sample variability exists; wild-harvested roots from older plants (>5 years) contain substantially higher miroestrol concentrations than cultivated younger plants.
Pueraria mirifica contains phytoestrogens including miroestrol, deoxymiroestrol, and isoflavones that bind to estrogen receptors (ERα and ERβ). These compounds activate estrogenic pathways in target tissues, promoting cellular proliferation and differentiation in vaginal epithelium. The phytoestrogens also influence bone metabolism by modulating osteoblast and osteoclast activity.
A randomized controlled trial (PMID: 17415017) demonstrated that Pueraria mirifica significantly reduces vaginal dryness and dyspareunia in postmenopausal women. The study showed improved vaginal health index and maturation, with cell composition shifting from 46:43:11 to 11:65:24 parabasal:intermediate:superficial cells. Evidence also suggests bone health benefits, though more research is needed to establish optimal dosing protocols. Most clinical studies have focused on menopausal symptoms with limited long-term safety data.
Pueraria mirifica may cause mild gastrointestinal upset, breast tenderness, and spotting in some users. Due to its estrogenic activity, it should not be used during pregnancy, breastfeeding, or by individuals with hormone-sensitive conditions like breast cancer. The herb may interact with hormone replacement therapy and anticoagulant medications. Consultation with healthcare providers is recommended before use, especially for those with existing medical conditions.
